Market capitalization | $2.40b |
Enterprise Value | $1.90b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.57 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-241.79m |
Free Cash Flow (TTM) Free Cash Flow | $-193.13m |
Cash position | $513.33m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
9 Analysts have issued a Apogee Therapeutics forecast:
9 Analysts have issued a Apogee Therapeutics forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.37 -0.37 |
1,133%
1,133%
|
|
EBITDA | -241 -241 |
104%
104%
|
EBIT (Operating Income) EBIT | -242 -242 |
104%
104%
|
Net Profit | -205 -205 |
98%
98%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Michael Henderson |
Employees | 196 |
Founded | 2022 |
Website | www.apogeetherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.